

CLAIMS

What is claimed is:

1. A method of treating a myelodysplastic syndrome in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF antibody, wherein said anti-TNF antibody competitively inhibits binding of TNF to monoclonal antibody cA2.
5
2. A method of treating a myelodysplastic syndrome in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF.
10
3. A method of treating a myelodysplastic syndrome in a human comprising administering to the human an effective TNF-inhibiting amount of chimeric anti-TNF antibody cA2.
- 15 4. A method for treating a myelodysplastic syndrome in a human comprising administering to the human at least one monoclonal antibody cA2, or a TNF binding fragment thereof.
5. A method of treating a myelodysplastic syndrome in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises an IgG1 constant region and competitively inhibits binding of TNF to monoclonal antibody cA2.
20

6. A method of treating a myelodysplastic syndrome in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises an IgG1 constant region and binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF.
7. A method of treating a myelodysplastic syndrome in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.
8. A method of treating a myelodysplastic syndrome in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5 and an IgG1 human constant region.
9. The method of Claim 7 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.
10. The method of Claim 8 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.: 4.

-158-

11. A method of treating a myelodysplastic syndrome in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to monoclonal antibody cA2.
- 5 12. The method of Claim 1 wherein said anti-TNF antibody is a humanized antibody.
13. The method of Claim 1 wherein said anti-TNF antibody is a human antibody.

11. A method of treating a myelodysplastic syndrome in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to monoclonal antibody cA2.